Posted by Michael Wonder on 14 Nov 2017
EMD Serono receives FDA approval for new Gonal-f RFF Redi-ject pen
13 November 2017 - Redesigned pen injector developed based on insights of healthcare professionals and fertility patients.
EMD Serono, received approval for a redesigned version of Gonal-f RFF Redi-ject (follitropin alfa injection) pen injector from the U.S. FDA. Originally approved in 2013, the new pen injector was reported to be easy to learn and easy to use in a simulated-use study including 86 women with infertility and 30 fertility nurses.
The redesigned Gonal-f RFF Redi-ject pen is the second version since its initial approval, underscoring EMD Serono's commitment to enhancing its product offering. Building on a strong foundation as the only fertility drug pen injector that does not require mixing or loading, the new pen offers a larger display window for dose readability.
